• In late June 2026, Merck announced multiple regulatory and clinical milestones, including new KEYTRUDA-based cancer approvals, an expanded CAPVAXIVE vaccine indication, positive Phase 3 data in ulcerative colitis, and an ADAP access agreement for its once-daily HIV treatment IDVYNSO in the United States.
• Together, these developments broaden Merck’s immunology, oncology, vaccine and HIV portfolios while also emphasizing access initiatives and global supply-chain expansion via an Abu Dhabi logistics hub collaboration.
• We’ll now examine how the IDVYNSO ADAP access deal, alongside oncology advances, may reshape Merck’s investment narrative and risk profile.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Merck Investment Narrative Recap

To own Merck today, you need to believe its late‑stage pipeline and recent launches can gradually rebalance dependence on KEYTRUDA while absorbing pricing and policy pressures. The June approvals for new KEYTRUDA combinations, the expanded CAPVAXIVE label, and positive tulisokibart data all speak to that effort. The IDVYNSO ADAP deal adds an access and HIV pillar, but it does not change the near‑term focus on oncology execution and regulatory or pricing risk around the core portfolio.

Among the latest announcements, the IDVYNSO agreement with the ADAP Crisis Task Force stands out for how it links innovation with broad access in a large U.S. HIV population supported by state programs. While smaller than oncology in absolute terms, this type of regimen and reimbursement footprint is exactly the sort of incremental growth driver analysts look for when assessing whether Merck’s 20‑plus planned launches can collectively offset future patent expiries and support its current valuation.

Yet against these growth drivers, there is a less visible risk around Congressional scrutiny of Merck’s overseas clinical trials that investors should be aware of...

Merck's narrative projects $76.5 billion revenue and $23.7 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a $14.8 billion earnings increase from $8.9 billion today.

Uncover how Merck's forecasts yield a $129.74 fair value, in line with its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were penciling in US$79.6 billion of revenue and US$26.2 billion of earnings by 2029, far above consensus, largely on faith that Merck’s oncology and chronic disease portfolio would keep winning even as dependence on a few products remained a concern; you should recognize that this is a much more optimistic story than the baseline view, and that both sets of expectations may shift as regulators, politicians and new trial data change the picture.

Explore 9 other fair value estimates on Merck - why the stock might be worth 22% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.